Cargando…

Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm, the most common clinical manifestations of which include arterial and venous thrombosis, bleeding and vasomotor/microvascular disturbances. Low-dose (81-100 mg) aspirin once daily, which irreversibly inhibits platelet...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cattaneo, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230439/ https://www.ncbi.nlm.nih.gov/pubmed/36632735 http://dx.doi.org/10.3324/haematol.2022.281388

Ejemplares similares

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
por: De Stefano, Valerio, et al.
Publicado: (2018)

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep
por: Accurso, Vincenzo, et al.
Publicado: (2020)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia
por: Yang, Erpeng, et al.
Publicado: (2022)

Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease
por: Pedersen, Oliver Buchhave, et al.
Publicado: (2021)

What is the meaning of P2Y12 reaction units in patients with essential thrombocythemia?
por: Goto, Shinya, et al.
Publicado: (2015)

Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
por: Tosetto, Alberto, et al.
Publicado: (2021)

Emerging treatments for essential thrombocythemia
por: Okoli, Steven, et al.
Publicado: (2011)

Essential Thrombocythemia in Children and Adolescents
por: Putti, Maria Caterina, et al.
Publicado: (2021)

What approaches to social prescribing work, for whom, and in what circumstances? A realist review
por: Husk, Kerryn, et al.
Publicado: (2019)

Person‐centred care in primary care: What works for whom, how and in what circumstances?
por: Ahmed, Anam, et al.
Publicado: (2022)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Intrapetrous internal carotid artery dissection and essential thrombocythemia: what relationship? A case report
por: D'Ambrosio, Daniele, et al.
Publicado: (2008)

Oncoplastic Breast Surgery: What, When and for Whom?
por: Macmillan, R. Douglas, et al.
Publicado: (2016)

Disentangling what works best for whom in comorbidity
por: Glozier, Nick, et al.
Publicado: (2022)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
por: McCurdy, Shannon R., et al.
Publicado: (2021)

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
por: Godfrey, Anna L., et al.
Publicado: (2018)

Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

VIEWPOINT: What counts as online patient feedback, and for whom?
por: Dudhwala, Farzana, et al.
Publicado: (2017)

Evolving Devices and Material in Transcatheter Aortic Valve Replacement: What to Use and for Whom
por: Chiarito, Mauro, et al.
Publicado: (2022)

Synthesis of the Evidence on What Works for Whom in Telemental Health: Rapid Realist Review
por: Schlief, Merle, et al.
Publicado: (2022)

Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review
por: Clerici, Bianca, et al.
Publicado: (2023)

Realist synthesis of intentional rounding in hospital wards: exploring the evidence of what works, for whom, in what circumstances and why
por: Sims, Sarah, et al.
Publicado: (2018)

Thromboembolic complication in Essential Thrombocythemia
por: Mozaheb, Zahra
Publicado: (2012)

Essential thrombocythemia: Busulphan revisited
por: Koduri, Prasad R.
Publicado: (2016)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Internet-based medical education: a realist review of what works, for whom and in what circumstances
por: Wong, Geoff, et al.
Publicado: (2010)

Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance
por: Paskins, Z., et al.
Publicado: (2022)

Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom?
por: Hollinger, Sabrina K., et al.
Publicado: (2016)

How does portfolio use affect self-regulated learning in clinical workplace learning: What works, for whom, and in what contexts?
por: van der Gulden, Rozemarijn, et al.
Publicado: (2022)

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera
por: Yoon, Seug Yun, et al.
Publicado: (2023)

Low-Risk Essential Thrombocythemia: A Comprehensive Review
por: Robinson, Andrew J., et al.
Publicado: (2021)

What is formulation in psychiatry?
por: Owen, Gareth
Publicado: (2023)

Honor-Based Abuse in England and Wales: Who Does What to Whom?
por: Bates, Lis
Publicado: (2020)

Moyamoya syndrome in an adult with essential thrombocythemia
por: Lazzaro, Marc A., et al.
Publicado: (2011)

Essential thrombocythemia: Rare cause of chorea
por: Venkatesan, Eswaradass Prasanna, et al.
Publicado: (2014)

Mutant calreticulin causes essential thrombocythemia
por: Shimoda, Kazuya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ufoql1g6bqfcgm25icfgi2q3ob